Global HealthPharmaceutical Regulations in Japan

Capacity Building

In order to improve access to medicines, it is important to not only provide practical guidance on local capacity building but also education and training.

In developing countries, access to medicines is obstructed by various factors, such as an inadequate public health insurance system and medical infrastructure, shortfalls in the human resources needed for the manufacture and quality management of medicines, the spread of counterfeit medicines and poverty.
JPMA and its members believe that capacity building in developing countries - specifically know-how transfer and educational training - is an important part of improving access to medicines.

1) Know-how transfer

JPMA and its member companies are providing technical assistance in cooperation with stakeholders on the manufacture and quality management of pharmaceuticals in order to improve access to medicine in developing countries.

2) Training

In developing countries, patients are not always able to receive appropriate medical care due to a lack of medical resources and a shortage of skilled healthcare professionals. JPMA and its member companies, in cooperation with developing country governments, are working to improve the ability of healthcare professionals involved in disease prevention, diagnosis, and treatment to improve healthcare in these countries.

3) Initiatives to improve access to healthcare

In developing countries, there are still many areas that suffer from insufficient medical access due to lack of social and medical infrastructure. Furthermore, in addition to a lack of healthcare knowledge, there continues to be areas that lack opportunities for people to learn about hygiene and disease prevention as well. JPMA and its member companies contribute to improve medical and health care via improving hygiene and awareness to medical care and access to healthcare for peoples living in local areas.

Initiatives by member companies
Financial assistance to cultivate and develop health workers Takeda Pharmaceutical Company Limited is implementing a donation program, the "Takeda Initiative", to cultivate and develop health workers in Africa through the Global Fund to Fight AIDS, Tuberculosis and Malaria. A total of 1 billion yen (US$12 million) is planned to be donated over 10 years from 2010 to 2019.
Acceptance of fellows and provision of training in developing countries

Astellas Pharma Inc. and Eisai Co., Ltd. have each accepted Fellows (trainees) from developing countries at their overseas offices through the WHO-TDR (WHO's Special Programme for Research and Training in Tropical Diseases) Clinical Research Fellowships. Clinical researchers were provided with specialist training and hands-on experience, in order to build capacity in clinical development in the developing world.

Astellas and Eisai accept fellows via WHO-TDR program (the neglected tropical disease medical special research and development program), and provide the opportunities of clinical research capacity building.

Since 2011, Astellas has contributed to the WHO TDR-IFPMA Fellowship Program in research and training in tropical diseases by having fellows, from Botswana, Ethiopia, and other countries working with Clinical Development/Project Management teams in the US and Europe to support Clinical R&D capacity building for treatment of infectious diseases in developing countries. In July 2014, a fellow from Ethiopia finished training.
In October 2015, a third fellow from Republic of Mali joined the R&D group and training will be provided until September 2016.

Eisai accepted fellows at Eisai Inc (NJ, USA), one from Nigeria in 2010, and the other from Columbia in 2011, providing training for management skills of clinical development and clinical studies. After going back to their countries, they have been playing leading roles in the diagnosis, and treatments of communcable diseases, and also the development of pharmaceuticals in their own countries. Eisai Tokyo Headquaters also accepted a medical school student from Indonesia in 2015, and provided an opportunity to enhance capacity builiding to support elimination of lymphatic filariasis in the country.

Improvement of diagnostic technology for dementia/provision of education on illnesses In India, Eisai is currently lending its support to the opening of memory clinics across the country to facilitate the early detection and treatment of dementia, and is engaged in educational programs for doctors as well as education on illnesses.
Technical cooperation for manufacturing of MR vaccine (mixed vaccine for measles and rubella) Kitasato Daiichi Sankyo Vaccine, a subsidiary of Daiichi Sankyo, currently provides technical support for the domestic manufacture of the first mixed vaccine for measles and rubella in Vietnam.
Mobile medical services to improve access to healthcare Daiichi Sankyo is operating mobile healthcare field clinics in order to contribute to the regions where medical infrastructure, doctors, and transportation to hospitals are all in insufficient supply in India and Tanzania.
Since 2011, the company has cooperated with NGOs, local governments and communities to provide immunizations to infants and small children, medical examinations for pregnant and parturient women, and other medical care services using mobile medical services, and has cultivated public health clinics for providing support for local activities.
Provision of education on diseases/patient education support programs using smartphones Astellas provides illness awareness and patient education support programs regarding "overactive bladders" for smartphone users that can be accessed around the world. Understanding towards patients who suffer from overactive bladders continues to be insufficient.
The intention of the aforementioned program is to have patients themselves deepen their understanding and work towards controlling their illness of their own accord through understanding regarding their illness and condition, physical activity instruction for improving symptoms, daily recordkeeping of symptoms, and so forth.
Financial assistance for Eradication of Malaria Sumitomo Dainippon Pharma supports the initiatives for eradication of malaria in a few countries in Asia and Africa. The company has cooperated with NPO, local governments and communities to provide insecticide-treated mosquito net, rapid diagnostic test kits for malaria, and educational activities in Zambia, Tanzania, and Indonesia, as well as advocacy initiatives in Japan.
Financial assistance to examine tuberculosis Sumitomo Dainippon Pharma supports initiatives to improve access to healthcare in developing countries. The company has cooperated with NPO to implement training and education of nurses in Bangladesh. In Haiti, the company has cooperated with NPO to implement regular medical examinations for tuberculosis and training of physicians.
Support Health Improvement for Mothers and Children Daiichi Sankyo launched an initiative through an international NGO, Plan International Japan, in the rural areas of Yunnan Province, which has one of the highest stunting rates in China.
Daiichi Sankyo is supporting activities for cultivating healthcare workers capable of contributing to better healthcare for children and mathers and for providing healthcare education to local residents.
Support health Improvement for mothers and children, Shionogi's initiative “Mother to Mother” Shionogi launched an initiative named “Mother to Mother”with an international NGO, World Vision Japan, in the rural areas of Narok Province in Republic of Kenya to improve the health of mothers, newborns and infants, and to support their independence at their medical practice by donating a portion of sales for Popon®S series in Japan and by the donation from Shionogi employees.
Action on Fistula Action on Fistula is led by the charity Fistula Foundation and funded by Astellas. By the completion of the three year program in 2017, the initiative had targeted to transform the lives of more than 1,200 women in Kenya living with this condition and to build capacity in the country to deliver ongoing surgeries in the long term. This initiative is establishing a fistula treatment network, increasing the number of fistula surgeons, and significantly boosting the number of surgeries that take place in the country. By the end of April 2016, 1,210 women in Kenya with obstetric fistula have successfully been treated with life changing reconstructive surgery. A major outreach program is now established with community workers identifying patients and encouraging them to access available treatment.

Page Top

  • Office of Pharmaceutical Industry Research(OPIR)
  • Global Health
  • Stop AMR
  • APAC